Research programme: peptide-drug conjugates - Phi Pharma

Drug Profile

Research programme: peptide-drug conjugates - Phi Pharma

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phi Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; HES-SO Valais-Wallis; Phi Pharma
  • Class Drug conjugates; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Leishmaniasis

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Research Leishmaniasis

Most Recent Events

  • 26 Apr 2017 Research programme: peptide-drug conjugates - Phi Pharma is available for licensing as of 26 Apr 2017. http://www.phi-pharma.com (Phi Pharma website, April 2017)
  • 26 Apr 2017 Phi Pharma has patent protection for peptide technology (Phi Pharma website, April 2017)
  • 12 Oct 2016 Phi Pharma and HES-SO Valais-Wallis agree to co-develop peptide-drug conjugates for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top